Casgevy Sales Climb to $99 Million in Quarter
The gene-editing therapy is now generating revenue, with CRISPR Therapeutics sharing profits with Vertex in a 60/40 split.
Updated on Nov. 2, 2026 in Biotech
CRISPR Therapeutics reported third-quarter 2026 sales of $99 million for Casgevy, its gene-editing therapy for sickle cell disease and beta-thalassemia, up 30% from the second quarter and nearly six times the year-ago quarter. Casgevy is a commercial product already on the market, so these are shipped-product sales rather than research-stage results.
Why it matters
Casgevy's growth shows a CRISPR-based therapy moving from approval into revenue, a milestone the gene-editing field has been working toward since the technique entered clinical use. Because Vertex runs the launch and the two companies split profits and costs 60/40, the revenue lands in CRISPR's books through a collaboration rather than as direct sales.
The figures come from CRISPR's quarterly financial report, which shows $99 million in Casgevy sales against a year-ago quarter that was roughly one-sixth that level. The company also reported $2.28 billion in cash and marketable securities, up from $1.98 billion at the end of 2025, while the net loss widened to $111.4 million. Whether the sales growth continues at this pace was not addressed in the extraction.
The players
CRISPR Therapeutics
A gene-editing company whose platform uses the CRISPR technique, with Casgevy as its first approved therapy and CTX310 in cl.inical development for severe hypertriglyceridemia.
Vertex Pharmaceuticals
A drug developer that runs the commercial launch of Casgevy and shares profits and costs with CRISPR Therapeutics in a 60/40 split.
The details
Casgevy is a gene-editing therapy that modifies a patient's own blood-forming stem cells using CRISPR, a technique that uses a guide molecule to direct a cutting enzyme to a specific spot in the genome. CRISPR Therapeutics does not book Casgevy sales itself; Vertex runs the launch, and the two companies split profits and costs 60/40. Because the revenue flows through this collaboration, CRISPR reports its share as collaboration income and net collaboration expense rather than as product sales. The company's net collaboration expense fell about 28% from a year earlier, which is part of why the sales growth matters to its overall financial picture.
Timeline
March 2026: CRISPR sold $585 million of convertible notes.
Third quarter 2026: Casgevy reported $99 million in sales.
Nov. 9, 2026: CTX310 Phase 1b data in severe hypertriglyceridemia is slated for a late-breaking talk at the American Heart Association meeting.
The Tech Race
Casgevy is the first CRISPR-based therapy to reach commercial revenue, and its quarterly sales now give investors a measurable read on whether gene editing can sustain a product business. CRISPR's pipeline is also moving forward, with CTX310 data for severe hypertriglyceridemia scheduled for a late-breaking presentation at the American Heart Association meeting on Nov. 9.
Casgevy is an approved therapy available to eligible patients with sickle cell disease and beta-thalassemia, and its growing sales reflect rising uptake. The extraction does not specify pricing, the number of treatment centers, or the eligibility criteria that govern access.
The takeaway
Watch the Nov. 9 American Heart Association presentation of CTX310 Phase 1b data, which will show whether CRISPR's pipeline can extend beyond its first approved product. Track the next quarterly report to see whether Casgevy's 30% sequential growth continues and whether net collaboration expense keeps falling.
What happens next
CTX310 Phase 1b data in severe hypertriglyceridemia will be presented at a late-breaking talk at the American Heart Association meeting on Nov. 9, 2026.
Further reading
For broader context on where gene-editing therapies are heading, explore the latest Biotech coverage.
